{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:36:42Z","timestamp":1762177002218},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40487-017-0048-0","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T12:15:05Z","timestamp":1496751305000},"page":"53-67","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Second-line Treatments for Advanced Gastric Cancer: A Network Meta-Analysis of Overall Survival Using Parametric Modelling Methods"],"prefix":"10.1007","volume":"5","author":[{"given":"Rebecca C.","family":"Harvey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,6]]},"reference":[{"key":"48_CR1","unstructured":"National Institute of Health and Care Excellence: Guidance scope for Oesophago-gastric cancer: assessment and management in adults. 2016. https:\/\/www.nice.org.uk\/guidance\/GID-CGWAVE0801\/documents\/final-scope . Accessed Jan 2017."},{"issue":"4","key":"48_CR2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5306\/wjco.v6.i4.73","volume":"6","author":"B Badiani","year":"2015","unstructured":"Badiani B, Maratea D, Messori A. Second-line treatments for advanced gastric cancer: interpreting outcomes by network meta-analysis. World J Clin Oncol. 2015;6(4):73\u20139.","journal-title":"World J Clin Oncol."},{"key":"48_CR3","unstructured":"National Institute of Health and Care Excellence. Capecitabine for the treatment of advanced gastric cancer\u2014Technical appraisal guidance. 2010. https:\/\/www.nice.org.uk\/guidance\/ta191 . Accessed Jan 2017."},{"key":"48_CR4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2288-11-61","volume":"11","author":"JP Jansen","year":"2011","unstructured":"Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Med Res Methodol. 2011;11:61.","journal-title":"BMC Med Res Methodol"},{"key":"48_CR5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jrsm.25","volume":"1","author":"MJNM Ouwens","year":"2010","unstructured":"Ouwens MJNM, Philips Z, Jansen JP. Network meta-analysis of parametric survival curves. Res Synth Methods. 2010;1:258\u201371.","journal-title":"Res Synth Methods."},{"key":"48_CR6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2012.10.019","volume":"16","author":"S Cope","year":"2013","unstructured":"Cope S, Ouwens MJNM, Jansen JP, Schmid P. Progression-free survival with fulvestrant 500\u00a0mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models. Value in Health. 2013;16:403\u201317.","journal-title":"Value in Health."},{"key":"48_CR7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ctrv.2014.11.004","volume":"41","author":"P Ladyzynski","year":"2015","unstructured":"Ladyzynski P, Molik M, Folynski P. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia. Cancer Treat Rev. 2015;41:77\u201393.","journal-title":"Cancer Treat Rev"},{"key":"48_CR8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2288-10-54","volume":"10","author":"BS Woods","year":"2010","unstructured":"Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol. 2010;10:54.","journal-title":"BMC Med Res Methodol"},{"key":"48_CR9","unstructured":"Hoyle M, Rogers G, Garside R et al. The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene, Addendum to the report submitted on 1st September 2008, Peninsula Technology, Assessment Group, Universities of Exeter and Plymouth. 2009. http:\/\/www.nice.org.uk\/nicemedia\/live\/11937\/43015\/43015.pdf . Accessed Jan 2017."},{"issue":"1","key":"48_CR10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1017\/S0266462305050154","volume":"21","author":"S Michaels","year":"2005","unstructured":"Michaels S, Piedbois P, Burdett S, et al. Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care. 2005;21(1):119\u201325.","journal-title":"Int J Technol Assess Health Care"},{"key":"48_CR11","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, Juni P, Moher D, Oxman AD et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ."},{"key":"48_CR12","unstructured":"Fedorov S. GetData graph digitizer version 2.26.0.20. 2002\u20132013. http:\/\/getdata-graph-digitizer.com\/ . Accessed January 2017."},{"key":"48_CR13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"48_CR14","unstructured":"Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011], The Cochrane Collaboration. http:\/\/www.cochrane-handbook.org . Accessed Jan 2017."},{"key":"48_CR15","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org . Accessed Jan 2017."},{"key":"48_CR16","unstructured":"Plummer M. JAGS: a program for analysis of bayesian graphical models using gibbs sampling. Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003), Vienna, Austria. ISSN 1609-395X."},{"key":"48_CR17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","volume":"7","author":"SP Brooks","year":"1998","unstructured":"Brooks SP, Gelman A. Alternative methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1998;7:434\u201355.","journal-title":"J Comput Graph Stat."},{"key":"48_CR18","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","volume":"47","author":"PC Thuss-Patience","year":"2011","unstructured":"Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer\u2014a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47:2306\u201314.","journal-title":"Eur J Cancer"},{"key":"48_CR19","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","volume":"31","author":"S Hironaka","year":"2013","unstructured":"Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31:4438\u201344.","journal-title":"J Clin Oncol"},{"key":"48_CR20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","volume":"15","author":"HE Ford","year":"2014","unstructured":"Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15:78\u201386.","journal-title":"Lancet Oncol."},{"key":"48_CR21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31\u20139.","journal-title":"Lancet"},{"key":"48_CR22","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2011.39.4585","volume":"30","author":"JH Kang","year":"2012","unstructured":"Kang JH, Lee SI, do Lim H, et al. Salvage chemotherapy for pre-treated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30:1513\u20138.","journal-title":"J Clin Oncol"},{"key":"48_CR23","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1200\/JCO.2012.48.3552","volume":"31","author":"A Ohtsu","year":"2013","unstructured":"Ohtsu A, Ajani JA, Bai YX, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013;31:3935\u201343.","journal-title":"J Clin Oncol"},{"key":"48_CR24","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224\u201335.","journal-title":"Lancet Oncol."},{"issue":"29","key":"48_CR25","doi-asserted-by":"crossref","first-page":"8811","DOI":"10.3748\/wjg.v21.i29.8811","volume":"21","author":"SM Kim","year":"2015","unstructured":"Kim SM, Park SH. Chemotherapy beyond second-line in advanced gastric cancer. World J Gastroenterol. 2015;21(29):8811\u20136.","journal-title":"World J Gastroenterol"},{"key":"48_CR26","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15:940\u20137.","journal-title":"Value Health."}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-017-0048-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T16:00:24Z","timestamp":1719244824000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40487-017-0048-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["48"],"URL":"https:\/\/doi.org\/10.1007\/s40487-017-0048-0","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}